Europese Unie - Nederlands - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel hydrochloride - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotische middelen - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

taw pharma (ireland) ltd. - lisinoprildihydraat 1,088 mg/ml - eq. lisinopril 1 mg/ml - drank - 1 mg/ml - lisinoprildihydraat 1.088 mg/ml - lisinopril

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

taw pharma (ireland) ltd. - amlodipinebesilaat 1,386 mg/ml - eq. amlodipine 1 mg/ml - suspensie voor oraal gebruik - 1 mg/ml - amlodipinebesilaat 1.386 mg/ml - amlodipine

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

essential pharma limited vision exchange building, triq it-territorjals, zone 1, central business district cbd 1070 birkirka - amlodipinebesilaat 1,4 mg/ml samenstelling overeenkomend met ; amlodipine 1 mg/ml - suspensie voor oraal gebruik - siliciumdioxide (e 551) ; sucralose (e 955) ; triglyceriden middellange keten - amlodipine

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

essential pharma limited vision exchange building, triq it-territorjals, zone 1, central business district cbd 1070 birkirka - lisinopril 2-water 1,09 mg/ml samenstelling overeenkomend met ; lisinopril 1 mg/ml - drank - citroenzuur 1-water (e 330) ; glycerol (e 422) ; hydroxyethylcellulose ; natriumbenzoaat (e 211) ; water, gezuiverd, - lisinopril

Europese Unie - Nederlands - EMA (European Medicines Agency)

viatris limited - clopidogrelbesilaat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotische middelen - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). het st-segment elevatie acuut myocardinfarct, in combinatie met asa in medisch behandelde patiënten in aanmerking komen voor trombolytische therapie. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. voor meer informatie refereer je naar sectie 5.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

stada arzneimittel ag stadastrasse 2-18 61118 bad vilbel (duitsland) - tadalafil 20 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polysorbaat 80 (e 433) ; talk (e 553 b) ; titaandioxide (e 171)

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bioq pharma b.v. - ropivacaïnehydrochloridemonohydraat 2,116 mg/ml - eq. ropivacaïnehydrochloride 2 mg/ml - oplossing voor infusie in toedieningssysteem - 2 mg/ml - ropivacaïnehydrochloridemonohydraat 2.116 mg/ml - ropivacaine

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

omega pharma nederland b.v. kralingseweg 201 3062 ce rotterdam - nicotineresinaat samenstelling overeenkomend met ; ; nicotine - zuigtablet - acesulfaam kalium (e 950) ; arabische gom (e 414) ; kaliumwaterstofcarbonaat (e 501 (ii)) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; muntsmaakstof ; natriumalginaat (e 401) ; natriumcarbonaat 0-water (e 500 (i)) ; polycarbofil calcium ; sucralose (e 955) ; xanthaangom (e 415), acesulfaam kalium (e 950) ; arabische gom (e 414) ; kaliumwaterstofcarbonaat (e 501 (ii)) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; mintsmaakstof ; natriumalginaat (e 401) ; natriumcarbonaat 0-water (e 500 (i)) ; polycarbofil calcium ; sucralose (e 955) ; xanthaangom (e 415)

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

omega pharma nederland b.v. kralingseweg 201 3062 ce rotterdam - nicotineresinaat samenstelling overeenkomend met ; nicotine - zuigtablet - acacia senegal ; acesulfaam kalium (e 950) ; calciumcarbonaat (e 170) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; menthol, racemisch (dl-vorm) ; muntsmaakstof ; natriumalginaat (e 401) ; natriumcarbonaat 0-water (e 500 (i)) ; pepermuntolie ; polycarbofil calcium ; sucralose (e 955) ; xanthaangom (e 415), acacia senegal ; acesulfaam kalium (e 950) ; calciumcarbonaat (e 170) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; menthol, racemisch (dl-vorm) ; mintsmaakstof ; natriumalginaat (e 401) ; natriumcarbonaat 0-water (e 500 (i)) ; pepermuntolie ; polycarbofil calcium ; sucralose (e 955) ; xanthaangom (e 415)